Latest News

Stay up to date with the latest stock market news from around the world. From breaking news written by our finance analysts to event-driven market news on a global scale.

NasdaqGS:FUNC
NasdaqGS:FUNCBanks

First United (FUNC) Net Margins Surge to 29.8%, Reinforcing Bullish Value Narrative

First United (FUNC) reported standout earnings growth of 54.4% over the past year, far outpacing its 5-year average of 5.3% per year. Net profit margins reached 29.8%, rising from 22.7% in the prior year, while shares are currently trading at $36.98, well below an estimated fair value of $68.47. With only one minor risk flagged and multiple rewards highlighted, including high-quality past earnings, expanding profit and revenue, and a strong value profile, the latest results point to improved...
NYSEAM:CATX
NYSEAM:CATXBiotechs

Perspective Therapeutics (CATX): Assessing Valuation After ESMO Data Release and Sharp Share Price Drop

Perspective Therapeutics revealed updated interim results from its Phase 1/2a trial of [212Pb]VMT-alpha-NET at ESMO Congress 2025, which sparked a sharp drop in the company’s share price as investors digested the latest efficacy signals. See our latest analysis for Perspective Therapeutics. This latest clinical trial update comes after a challenging year for Perspective Therapeutics. Following a brief rally in anticipation of new data, the 1-day share price return slipped by 2.5%, and the...
XTRA:GXI
XTRA:GXILife Sciences

Should FDA Approval of Lasix ONYU Prompt a Closer Look at Gerresheimer’s (XTRA:GXI) Growth Path?

On October 13, 2025, SQ Innovation received FDA approval for Lasix ONYU, a combination product featuring Gerresheimer’s proprietary on-body infusor for at-home subcutaneous drug delivery in select congestive heart failure patients. This milestone showcases Gerresheimer’s technological capabilities in advanced drug delivery devices and highlights its growing position as a full-service partner to pharmaceutical companies embracing home-based care. Next, we’ll explore how the FDA-backed rollout...
NasdaqGM:ARTV
NasdaqGM:ARTVBiotechs

Artiva Biotherapeutics (ARTV) Is Up 71.1% After FDA Fast Track Win for Novel Arthritis Therapy – What's Changed

Artiva Biotherapeutics recently announced that the FDA has granted Fast Track Designation to its AlloNK (AB-101) therapy in combination with rituximab for the treatment of refractory rheumatoid arthritis, marking a first for deep B-cell depleting therapies in this indication. This development highlights Artiva's focus on addressing a large unmet need in autoimmune disease with an outpatient-ready, community-administered cellular therapy. We'll explore how Fast Track status for AlloNK and...
SEHK:9863
SEHK:9863Auto

3 Asian Stocks Estimated To Be Trading At Discounts Of Up To 45.3%

Amid ongoing global market volatility and economic uncertainties, Asian markets have been navigating a complex landscape marked by trade tensions and fluctuating investor sentiment. In this environment, identifying undervalued stocks can offer potential opportunities for investors seeking value; these stocks may be trading below their intrinsic worth due to broader market conditions rather than company-specific issues.
ENXTPA:ALFRE
ENXTPA:ALFREProfessional Services

Freelance.com (ENXTPA:ALFRE) Earnings Growth Tops Narrative, But Guidance Flags Future Caution

Freelance.com (ENXTPA:ALFRE) delivered earnings growth of 53.2% over the past year, outpacing its robust five-year average annual growth rate of 20.2%. Net profit margins improved to 2.2% from 1.6% a year ago, while the stock trades at €2.22, a notable discount to its estimated fair value of €9.02 and well below peer valuation multiples. While recent results highlight consistently high-quality earnings and increasing profitability, the major risk for investors is the projected 0.3% annual...